US · ECOR
electroCore, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Rockaway, NJ 07866
- Website
- electrocore.com
Price · as of 2024-12-31
$6.64
Market cap 60.61M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $114.84 | +1,629.52% |
| Intrinsic Value(DCF) | $796.66 | +11,897.89% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $113.40 | $14,516.93 | $4.09 | $0.00 | $0.00 |
| 2019 | $9.28 | $5.78 | $47,332.29 | $0.00 | $0.00 |
| 2020 | $32.10 | $311.92 | $1,162.87 | $0.00 | $0.00 |
| 2021 | $8.18 | $118.24 | $735.27 | $0.00 | $0.00 |
| 2022 | $3.76 | $19.13 | $270.53 | $0.00 | $0.00 |
| 2023 | $6.81 | $37.11 | $9,156.07 | $0.00 | $0.00 |
| 2024 | $14.10 | $114.84 | $6,932.19 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates electroCore, Inc.'s (ECOR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $114.84
- Current price
- $6.64
- AI upside
- +1,629.52%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$796.66
+11,897.89% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ECOR | electroCore, Inc. | $6.64 | 60.61M | +1,630% | +11,898% | — | — | -8.88 | 13.99 | 4.19 | -8.96 | — | 13.99 | 84.97% | -48.30% | -47.20% | -158.63% | 945.74% | -65.00% | 0.55 | — | 1.78 | 1.46 | -0.06 | -5351.00% | 5709.00% | -5329.00% | -6.59% | -0.76 | 544.51% | 0.00% | 0.00% | 0.00% | -8.03 | -14.06 | 3.88 | -7.53 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| HYPD | Hyperion DeFi, Inc. | $2.82 | 16.06M | +1,294% | +147,433% | — | — | -0.03 | -0.10 | 23.10 | -0.23 | -0.21 | -0.10 | -6749.50% | -85004.58% | -86888.57% | 2432.03% | -1558.51% | -307.07% | -0.86 | -19.62 | 0.17 | 0.13 | -0.20 | 1253.00% | 141402.00% | 890.00% | -2286.39% | -1.88 | -968.35% | 0.00% | 0.00% | 0.00% | -0.21 | -0.34 | 182.16 | -122.68 |
| NMTC | NeuroOne Medical Technolo… | $0.67 | 33.87M | +8,902% | +225,949% | — | — | -7.93 | 4.04 | 2.36 | -7.40 | — | 4.07 | 67.30% | -34.94% | -29.80% | -91.34% | -2161.45% | -44.63% | 0.04 | -12.65 | 4.44 | 3.40 | 2.09 | -8043.00% | 25035.00% | -7378.00% | -10.21% | -1.23 | -1492.81% | 0.00% | 0.00% | 18.29% | -5.27 | -7.63 | 1.84 | -4.87 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| RBOT | Vicarious Surgical Inc. | $2.04 | 13.19M | — | — | — | — | -0.87 | 1.17 | — | -0.32 | — | 1.17 | 0.00% | — | — | -87.40% | -511.76% | -67.41% | 0.30 | — | 6.74 | 6.40 | -0.07 | -2658.00% | — | -2163.00% | -91.59% | -6.52 | -385.51% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -4.95 |
| RNXT | RenovoRx, Inc. | $0.88 | 32.36M | — | — | — | — | -2.56 | 5.04 | 525.37 | -1.43 | — | 5.04 | 100.00% | -25511.63% | -20497.67% | -1192.69% | 333.89% | -183.93% | 0.06 | — | 4.10 | 3.77 | 0.63 | -2600.00% | — | -1093.00% | -40.45% | -4.78 | 278.10% | 0.00% | 0.00% | 25.24% | -1.43 | -1.72 | 365.46 | -8.52 |
| YI | 111, Inc. | $7.91 | 68.56M | +302% | -56% | — | — | -25.62 | -0.83 | 0.04 | 13.27 | — | -0.83 | 5.76% | 0.01% | -0.45% | 3.39% | -0.26% | -0.71% | -0.40 | 0.07 | 1.13 | 0.47 | -8.35 | -8386.00% | -366.00% | -15422.00% | 46.56% | 0.11 | -30.18% | 0.00% | 0.00% | 8.50% | 154.56 | 1.32 | 0.02 | 3.48 |
| ZYXI | Zynex, Inc. | $0.09 | 2.73M | +47,067% | +3,167% | +949% | +1,186% | 78.41 | 6.57 | 1.22 | 24.92 | — | 29.13 | 79.50% | 3.11% | 1.56% | 7.32% | 6.70% | 2.31% | 2.07 | 2.51 | 4.46 | 3.42 | 3.17 | -6667.00% | 436.00% | -2663.00% | 5.17% | 0.75 | 16.45% | 0.00% | 0.30% | 6.66% | 44.90 | 22.15 | 1.40 | 4.28 |
About electroCore, Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
- CEO
- Daniel S. Goldberger
- Employees
- 73
- Beta
- 0.51
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($796.66 ÷ $6.64) − 1 = +11,897.89% (DCF, example).